Receptor News and Research

RSS

Lactoferrin yogurt helps preserve iron stores in women with gestational diabetes

In a double-blind pilot trial, lactoferrin-enriched yogurt added to routine iron supplementation helped prevent ferritin decline in pregnant women with gestational diabetes and reduced iron stores. The intervention was well tolerated and produced modest changes in selected gut bacteria, but did not significantly improve anemia or metabolic outcomes.

15 Jul 2026

Researchers rank 11 preeclampsia therapies as top candidates for further development

Researchers ranked 83 preclinical candidates for preventing or treating preeclampsia and eclampsia, identifying 11 as having high potential for further development. The analysis also revealed limited target diversity, moderate bias, inactive programs, and animal models that may not fully represent human pregnancy

15 Jul 2026

Brain’s immune cells play key role in maintaining stability of neuronal networks in Alzheimer's disease

Researchers at Trinity College Dublin have discovered that microglia – the main immune cells of the brain – play a critical role in maintaining the stability of neuronal networks in Alzheimer's disease.

15 Jul 2026

Self-assembling antibody drugs successfully target multiple cancer receptors

Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drug, often given to patients for whom standard chemotherapy has not worked.

15 Jul 2026

GLP-1 receptor activation linked to lower depression and bipolar disorder odds

Genetic analyses linked BMI-related GLP-1 receptor activation to better mental well-being and lower odds of major depressive disorder and bipolar disorder. The findings do not prove that GLP-1 receptor agonist drugs treat psychiatric conditions, and randomized clinical trials are still needed.

15 Jul 2026

Cell death crosstalk network drives acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) remains one of the deadliest complications of severe infections, sepsis, trauma, and viral pneumonia, yet decades of research have produced few targeted therapies capable of improving patient outcomes.

14 Jul 2026

Semaglutide dose may matter more than weight loss for heart health

The study shows semaglutide's cardiovascular benefits are more closely tied to attained dose than weight loss, challenging existing treatment assumptions.

14 Jul 2026

Researchers uncover hidden mechanism behind cancer-linked SPOP mutations

Mutations to the protein SPOP are widespread in cancer, yet many remain poorly understood. To address this gap, St. Jude Children's Research Hospital scientists obtained structures of SPOP in both the presence and absence of these mutations.

13 Jul 2026

GLP-1 weight loss may reduce first-impression penalties in relationships and hiring

An NBER working paper found that GLP-1 initiation and associated weight loss were followed by higher partnership formation among initially single women and greater employment entry among women who were not employed. The findings suggest that part of the female obesity penalty may arise when prospective partners and employers form first impressions, although the observational analysis did not directly prove discrimination

13 Jul 2026

Nearly one in 10 Britons use or want weight-loss medication

The prevalence of GLP-1 receptor agonists for weight management in Great Britain highlights public interest and concerns over safety and prescribing practices.

13 Jul 2026

Study links GLP-1 treatment to fewer alcohol drinking days

Current GLP-1 receptor agonist prescriptions were associated with modestly lower AUDIT-C scores in a large, diverse US cohort. The difference appeared to reflect less frequent drinking rather than fewer drinks per occasion or fewer binge-drinking episodes.

13 Jul 2026

Gut microbiota may shape eating behavior and guide new obesity treatments

The review shows how gut microbiota may influence appetite, food reward, inflammation, and energy balance through the gut-brain axis. Microbiota-targeted approaches could support future treatments for obesity and eating disorders, but clinical evidence remains limited.

12 Jul 2026

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, suggests a study in preclinical models co-led by researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham.

12 Jul 2026

Harvard University hosts the world's largest conference dedicated to longevity biotechnology

The 13th Aging Research & Drug Discovery (ARDD) Meeting, the world's largest conference dedicated to longevity biotechnology, will take place from October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University.

11 Jul 2026

Insurance denials for brand-name drugs surge over past six years

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the American Enterprise Institute found that insurance denials of first attempts to fill prescriptions for brand-name prescription drugs with no generic competitors increased more than two-thirds between 2018 and 2024.

11 Jul 2026

GLP-1RAs linked to lower risk of amputation in diabetes with PAD

Research indicates GLP-1RAs may decrease limb complications in type 2 diabetes with PAD, though more randomized studies are required to confirm efficacy.

10 Jul 2026

GLP-1 exposure in pregnancy does not clearly raise major birth defect risk

A systematic review and meta-analysis of seven cohort studies involving more than 40,000 GLP-1 receptor agonist-exposed pregnancies found no statistically significant increase in major congenital malformations or several other adverse pregnancy outcomes. However, the evidence was low or very low certainty, and a urinary malformation signal based on unadjusted data requires cautious interpretation.

10 Jul 2026

Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated weight-loss effect among GLP-1 receptor agonists tested in adults with mental illness and obesity or related metabolic risk. The authors cautioned that the findings remain preliminary because the evidence base was small, heterogeneous, and largely indirect.

9 Jul 2026

GLP-1 drugs may reduce lung scarring from Long COVID in diabetic patients

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well.

9 Jul 2026

University of Malaga scientists find way to improve morphine treatments

Scientists at the Department of Cell Biology of the University of Malaga have taken a step forward in the search for more effective treatments for pain with a new study that continues advancing in mitigating the addictive effects of morphine -one of the main drugs used for this purpose- as well as the development of analgesic tolerance to this drug.

9 Jul 2026